Neurological Biomarkers Market Foreseen to Grow Exponentially Over 2017 – 2025
The University of British Columbia and the Karolinska Institute in Sweden have set up biobanks that provide necessary resources and information for biomedical research. Alzheimer’s is the most common form of dementia affecting 12 million people. Neuroimaging and neuropsychological probes can help predict Alzheimer before behavioral tests diagnose. Thus pre-assessment tests such as Positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) are driving the demand for neurological biomarkers.
Neurological Biomarkers Market: Dynamics
The introduction of newer neurological biomarkers is expected to play a crucial role in helping neuropathologists in the characterization and selection of suitable treatment strategies. Moreover, with the advent of telehealth and personalized medicine, there is an emerging trend of single-cell biosensors as it may help integrating large-scale clinical and molecular information.
These biomarkers are used in patients suffering from acute ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage and traumatic brain injury. Recovery from such neurocritical disease depends on how well the patient mitigates. In such situations, procurement of imaging studies or a good examination may be delayed due to the complexities involved. This shortcoming has further fueled the demand for biomarkers. The market is also experiencing recent trends with the researches undertaken on novel radiotracers, miRNA, and integration of systems biology into routine biomarker validation.
The neurological market is expected to witness growth owing to the various technological developments, the expansion in application and rise in the incidence of neurological disorders such as Alzheimer's, Parkinson’s and stroke. But the industry has certain restraints such as reproduction of positive trial results, the absence of pre-analytical tests and failure to investigate the efficiency of the biomarker as compared to previous one.
Furthermore, the demand for these biomarkers is expected to propel as the demand for neurological care is increasing. In America, there are around 5.4 million people diagnosed with Alzheimer’s disease. The number is expected to triple to 16 million by 2050. The demand for procedural specialties is more as compared to on procedural specialties. This statement can be justified by the fact that the Medicare payment grew by 84% for procedural specialties and only 48% for non-procedural specialties.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/16303
In terms of geography, the global neurological biomarkers market has been divided into five regions including North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. North America has a major revenue share in the neurological biomarkers industry as many prominent market players are present in this region, the number of R&D projects carried out and the government funding received by academic universities to undertake research. For instance in August 2015, researchers, patients and various non-profit organizations participated in the Imaging Dementia -- Evidence for Amyloid Scanning (IDEAS) study. The USD 100 million project aims to study the utility of amyloid PET imaging to diagnose dementia, Alzheimer’s and cognitive impairment.
Asia-Pacific is the fastest growing region as the region offers huge population base, high incidence rate of neurological abnormalities, entry of new market players and huge aging population. In developing economies such as India and China, new industry players are trying to establish their market presence by developing the generic version of the biomarker, through contract research organizations. This has further helped in reducing the manufacturing cost for the company and other production related cost.
TOC Sentence Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/16303
Neurological Biomarkers Market: Key Players
Key players in the neurological biomarkers industry are Myriad RBM, Proteome Sciences, QIAGEN, Thermo Fisher Scientific, AbaStar MDx, Acumen Pharmaceuticals, Abiant, Aepodia, Athena Diagnostics, ImmunArray, Quanterix and Cisbio Bioassays.
To view complete report @ http://www.persistencemarketresearch.com/market-research/neurological-biomarkers-market.asp
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Persistence Market Research Pvt. Ltd
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurological Biomarkers Market Foreseen to Grow Exponentially Over 2017 – 2025 here
News-ID: 603731 • Views: 212
More Releases from Persistence Market Research
The Outpatient Home Therapy Market to witness an overall with respect to growth …
Outpatient home therapy provides treatment at the patient’s home. There need for outpatient home therapy is growing and more facilities are added to the services. Outpatient home therapy provides extra comfort to the patients and is regulated by the Medicare and Medicaid programs. Home therapy is useful when patients are not able to travel to the healthcare units due to lack of transportation or the patient may not be able
The Meningococcal Vaccines Market to scale high in the next decade
The meningococcal vaccine market has expanded to a significant extent over the past few years in correspondence to the parent market. Constant research and development in meningococcal vaccines for various meningococcal disease preventive applications, coupled with the sanctions of subsidy & support of government organizations for immunization program are among the significant factors that are anticipated to drive the growth of the meningococcal vaccine market during the forecast period. Expansion of
The Immunoassay Interference Blocker Market to be on the escalation mode in the …
The rapidly increasing prevalence of chronic diseases and the growth of the aging population across the world are among factors that are expected to increase the need for biochemical testing for the management of chronic diseases. The global increase in aging population is expected to increase the demand for diagnostic kits and reagents for the detection of age-related as well as other chronic conditions, which is expected to boost the
The Orthopedic Surgical Robots Market to foresee growth in the next 10 years
Orthopedic surgical robots have gained immense popularity over the years. Consistent advancements in the technology for orthopedic surgical robots, the availability of orthopedic surgical robots across the globe, and increase in government funding and investments by manufacturers for the development of orthopedic surgical robots are among the primary factors that are anticipated to fuel the demand for orthopedic surgical robots during the forecast period. According to the latest research by PMR,
More Releases for Biomarkers
Biomarkers Market Fragmented by 2025
Global Biomarkers Market: Snapshot The global biomarkers market is witnessing a tremendous rise in its valuation, thanks to the increase in diagnostic applications of biomarkers. The augmenting investments for research and development activities in the pharma and biotech companies, rising number of CROs, and the low cost associated with the clinical trials in emerging economies are also boosting this market. Going forward, the high prevalence rate of cancer and novel initiatives for
Cancer Biomarkers Market: Regional Overview
Cancer is the second-leading cause of death worldwide (World Health Organization). There were around 14 million new cases of cancer reported across the globe in 2012 and the incidence rate is expected to increase by around 70% by 2030 (WHO). The most common cancer types are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer. Cancer therapies are expensive and the cost rises with increase in complexity or stage
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Biomarkers Market : Analysis & Trends 2023
Global Biomarkers Market A biomarker refers to a biological molecule or gene that is used to effectively and accurately evaluate pharmacologic responses, pathogenic procedures, and biological procedures. Also known as a molecular marker or signature molecule, biomarkers are found in blood, other body fluids, and tissue. Extensively used to see the body’s response to a particular treatment for a disease or condition, biomarkers assist medical professionals to take effective clinical decisions
Global Vocal Biomarkers Market
The Global Vocal Biomarkers Market is estimated to be valued at US$ 6.4 million by 2017 and is projected to expand at an astounding CAGR of 65.7% from 2017 to 2028, as analyzed by Coherent Market Insights. Vocal biomarkers enabling early diagnosis and being a non-invasive procedure are analyzed to be major factor fueling uptake of this disruptive technology over the forecast period (2017–2028). Mental and physical conditions such as anxiety
SMi present their 4th annual conference on Biomarkers Summit Monday 31st January & Tuesday 1st February 2011 Crowne Plaza The-City, London, UK Don’t Miss Out - Visit to register your place today http://www.smi-online.co.uk/preclinical-biomarkers.asp Sponsored by Caprotec Cell Signalling Technology GVK Bio Selventa Millipore Quest Diagnostics RBM SMi’s highly anticipated 4th annual Biomarkers Summit is fast approaching, and time is running out